Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.58
$0.063.95%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.76M | 53.40M | 45.67M | 38.05M | 59.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.76M | 53.40M | 45.67M | 38.05M | 59.65M |
| Cost of Revenue | 29.90M | 24.32M | 29.29M | 25.81M | 22.50M |
| Gross Profit | 29.87M | 29.08M | 16.38M | 12.25M | 37.16M |
| SG&A Expenses | 11.68M | 12.19M | 13.34M | 14.41M | 14.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.14M | 49.48M | 54.57M | 52.84M | 51.59M |
| Operating Income | 4.63M | 3.92M | -8.91M | -14.79M | 8.06M |
| Income Before Tax | 5.16M | 4.15M | -9.59M | -15.15M | 6.77M |
| Income Tax Expenses | 1.25M | 1.22M | 18.00K | -456.00K | -79.00K |
| Earnings from Continuing Operations | 3.91 | 2.93 | -9.61 | -14.69 | 6.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.91M | 2.93M | -9.61M | -14.69M | 6.85M |
| EBIT | 4.63M | 3.92M | -8.91M | -14.79M | 8.06M |
| EBITDA | 5.96M | 5.22M | -7.62M | -13.53M | 9.30M |
| EPS Basic | 0.06 | 0.04 | -0.13 | -0.20 | 0.12 |
| Normalized Basic EPS | 0.05 | 0.04 | -0.08 | -0.13 | 0.07 |
| EPS Diluted | 0.02 | 0.00 | -0.14 | -0.22 | 0.02 |
| Normalized Diluted EPS | 0.02 | 0.01 | -0.09 | -0.13 | 0.04 |
| Average Basic Shares Outstanding | 293.69M | 290.11M | 292.51M | 291.24M | 285.09M |
| Average Diluted Shares Outstanding | 335.46M | 331.89M | 300.18M | 302.74M | 312.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |